ARCH raises $3 billion fund to invest in biotech startups; Biden administration to widen access to monkeypox vaccine

Taking stock of the drug industry, from the lab to the medicine chest ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by   STAT+: ARCH Venture Partners raises $3 billion fund to invest in biotech startups despite brutal stock downturn By Matthew Herper Adobe The company has become well known in biotech sectors for its bold investments in new technologies going back to Illumina. Read More Biden administration to widen access to monkeypox vaccine By Helen Branswell Chip Somodevilla/Getty Images In a bid to contain the monkeypox outbreak, the White House said Tuesday that more vaccine would be made available to people thought to be at high risk. Read More Opinion: FDA: Don't rush a move to change the Covid-19 vaccine composition By John P. Moore and Paul A. Offit Adobe Everyone would gain from having deeper insights into the performance of Covid-19 vaccines based on the Omicron variants of SARS-CoV-2. Read More Sponsor content by InCrowd ASCO 2022 Real-Time Roundup The 2022 Annual Meeting of the American Society of Clinical Oncology (ASCO) took place in person from June 3rd to the 7th. This year, InCrowd surveyed 92 attending oncologists to explore what attendees found most exciting about the tumor type data presented. Download the ASCO 2022 Real-Time Roundup to see the results. Explore the report today. In a doctor's suspicion after a miscarriage, a glimpse of expanding medical mistrust By Eric Boodman Chantal Heijnen for STAT To restrict abortions is to prevent evidence-based care, said one OB-GYN, but it also affects other medical encounters, too. Read More Wednesday, June 29, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser